Keeping pace with the evolving global landscape in vaccine development
Hear from a panel of Life Science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space. What has been COVID-19's impact on drug development and the regulatory landscape? Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage. Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.
Unlock the Power of Data Review & Collaboration: Maximizing Trial Success
Join us to discover how leveraging dynamic workflows to review, query, track, and collaborate cross-functionally in a clinical trial can result in better trial conduct, potential study amendments, and evolving clinical strategies.
Partnering with NHS in a crisis: The role for industry
In this interactive webinar, brought to you by IQVIA, we will explore the critical role for mutually beneficial partnership between the pharmaceutical industry and the NHS in helping to deliver better outcomes for patients, especially as critical efficiencies need to be identified in the wake of this global pandemic.
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.
Economic Impact of Representativeness in Clinical Trials: How Real-World Data Can Help
This panel of real-world evidence (RWE) experts explore the economic impact and role of RWE in improving representativeness of research.
How to Supercharge Real World Evidence Generation in Phase IV Trials
It's no secret that Phase 4 trials are incredibly time consuming, costly, and pose major challenges for sponsors and CROs alike. Whether it's Long Term Follow Up (LTFU), Rollover, and Observational studies, or Registry and Consumer Health studies, sponsors often struggle to recruit and retain large numbers of participants. They also have difficulties addressing post-marketing commitments to assess long term drug safety and efficacy.
Patient centric sampling in pediatric clinical trials- successes, challenges and how to overcome them
Patient centric blood sampling is an approach for the collection of high quality samples for the determination of pharmacokinetic, pharmacodynamic and clinical chemistry endpoints. The technologies offer the potential to collect high quality samples from patients away from the centralized clinical settings, such as in the home, thus putting the needs of the patient at the center. This panel discussion will introduce attendees to the technologies available, and through the presentation of case studies, will explore the benefits and challenges of implementing these technologies for pediatric clinical trials. This will be followed by a lively debate including questions from the audience.
Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access
Hear three experts address systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.
Using AI and Technology to Streamline Post-Stroke Patient Journeys to Cardiology
Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. They will share recent experience and data on how the latest innovations and platforms are improving the cryptogenic stroke care pathway.
Webcast: Taking the Complexity Out of Leveraging Health Plan Price Transparency Data
NTT DATA and Snowflake will discuss how to navigate the challenges of newly available health plan pricing transparency data due to the CMS Transparency in Coverage ruling. Our data model powered by Snowflake provides a comprehensive solution that allows provider negotiation teams to use this data to their competitive advantage and ensures high value utilization through easy consumption. We will walk through the three most important components of this solution that enable users to compare negotiated rates down to the procedure code level across facilities with incorporated metrics. The session includes a live demo of the sample executive reports that can be produced per client basis followed by an informative discussion on Snowflake's strategy in the healthcare space.
Creating Digital Biomarkers with Real-World and Existing Data by Xtalks
In this free webinar, learn how to leverage real-world data and existing digital health data to develop and validate digital biomarkers. Attendees will learn what to look for in a digital biomarker and what it takes to validate one. The featured speakers will discuss key success factors in reusing existing digital health data and some of the regulatory and clinical decision-making considerations. Attendees will also learn how to manage patient privacy issues.
Expediting drug product development and commercialization in global markets with global filing strategies
In this webinar, we will discuss the differences and commonalities among major global agencies, including US FDA, EMA, and China NMPA. Building upon that, we will discuss approaches to build a robust data package that satisfies expectations from global health authorities for clinical and commercial regulatory filings. We will share real-world case studies of how WuXi STA supported clients with their China filing strategies and expedited development and commercialization in China.
Beyond the payment variance report: How to resolve common, costly underpayment issues
In this webinar, experienced revenue cycle operators will discuss the new report's findings, common issues related to payer adjudication and the gaps seen in revenue cycle processes that often lead to underpayments. Speakers will also provide an overview of effective resolution strategies that have been deployed across more than 200 hospitals nationwide to tackle these very problems.
Decentralized trial solutions for complex clinical trials
Veristat shares their expertise and lessons learned from conducting a natural history study for a rare pediatric disease, which not only included virtual components from the start, but had to pivot mid-way to add in additional virtual visits during the pandemic lockdowns. This case study illustrates the challenges and flexible solutions that ensured the continued success of the study. Join us as we share the strategies that were deployed to improve the patient experience.
FDA Guidance Documents: Shaping the Future of RWD Curation and RWE Innovation
IQVIA's Mui Van Zandt, BMIS and Raina Olexa, MS lead a conversation on embracing FDA's guidance on the use of RWD, and how your organization can navigate data quality, curation, and management challenges for better research. Â Â
Webcast: Strategies to Simplify Insurance Discovery
Self-pay accounts are far more time-consuming and costly to collect on than those billed to commercial payers. Unfortunately, they're on the rise. To protect your margins in unpredictable financial times, it's crucial to find available coverage whenever and wherever you can.Â
Measuring the intangible- what is the true value of a “patient centric” initiative
In this webinar, brought to you by the company behind A Life in a Day, patient centricity experts will draw from their own experiences to debate questions around how and why to measure these initiatives. Is it important to measure impact and prove outcomes, or is it enough to improve the patient experience for its own sake? Is it even possible to create meaningful measurements for patient centric activities, and if so, what do those measurements look like?
Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.Â
The Future of Real-World Evidence: Pharma’s Next Moves, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the importance of real-world evidence (RWE) as an end-to-end capability. Attendees will gain insights into meaningful ways to leverage RWE for business growth today and in the future. The featured speakers will discuss obstacles and roadblocks to future success and implementation.